Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Arcus Biosciences, Inc. (RCUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 4 Jarrett Jennifer (COO) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Sold 21,369 shares @ $19.99, valued at $427.2k
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update • Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical Oncology ; Fc-silent anti-TIGIT monoclonal antibody domvanalimab continued to demonstrate clinically meaningful improvements over anti-PD-1 monotherapy across all measures evaluated, including progression-free survival, overall response rate, and duration of response • Initiated the dose-expansion phase of the Phase 1b ARC-20 study of AB521, a potential best-in-class HIF-2a inhibitor, in clear-cell renal cell carcinoma patients at a dose of 100 mg daily; pharmacokinetic, pharmacodynamic and safety data, along with any preliminary signs of anti-tumor activity from the d..."
07/31/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/06/2023 SC 13D/A GILEAD SCIENCES, INC. reports a 35% stake in ARCUS BIOSCIENCES, INC.
07/05/2023 4 Azoy Alexander (Chief Accounting Officer) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Sold 1,018 shares @ $20.41, valued at $20.8k
06/30/2023 4 GILEAD SCIENCES, INC. (10% Owner) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Bought 1,010,000 shares @ $19.26, valued at $19.5M
06/16/2023 4 Tang Carolyn C. (General Counsel) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Disposed/sold 2,892 shares @ $19.35, valued at $56k
06/16/2023 4 Jarrett Jennifer (COO) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Sold 12,563 shares @ $19.35, valued at $243.1k
06/16/2023 4 Jaen Juan C. (President) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Gifted 6,000 shares @ $0
Disposed/sold 4,820 shares @ $19.35, valued at $93.3k
06/16/2023 4 ROSEN TERRY J (CEO) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Disposed/sold 8,762 shares @ $19.35, valued at $169.5k
06/16/2023 4 Lambert Nicole (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Granted 6,800 shares @ $0
Granted 19,500 options to buy @ $19.6, valued at $382.2k
06/16/2023 4 PERLMAN ANDREW J (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Granted 6,800 shares @ $0
Granted 19,500 options to buy @ $19.6, valued at $382.2k
06/16/2023 4 Lacey David L. (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Granted 6,800 shares @ $0
Granted 19,500 options to buy @ $19.6, valued at $382.2k
06/16/2023 4 Ribas Antoni (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Granted 6,800 shares @ $0
Granted 19,500 options to buy @ $19.6, valued at $382.2k
06/16/2023 4 Machado Patrick (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Granted 6,800 shares @ $0
Granted 19,500 options to buy @ $19.6, valued at $382.2k
06/16/2023 4 KANEKO YASUNORI (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Granted 6,800 shares @ $0
Granted 19,500 options to buy @ $19.6, valued at $382.2k
06/16/2023 4 FALBERG KATHRYN E (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Gifted 50,504 shares @ $0
Granted 6,800 shares @ $0
Granted 19,500 options to buy @ $19.6, valued at $382.2k
06/16/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 15, 2023 A. Cash Compensation Annual cash retainers each paid quarterly, in arrears, as follows: 1. Retainer for each non-employee member of the Board: $45,000 2. Additional retainer for Lead Independent Director: $25,000 3. Additional retainer for Chair of Audit Committee: $20,000 4. Additional retainer for Chair of Compensation Committee: $15,000 5. Additional retainer for Chair of Nominating and Corporate Governance Committee: $10,000 6. Additional retainer for non-Chair members of Audit Committee: $10,000 7. Additional retainer for non-Chair members of Compensation Committee: $7,500 8. Additional retainer for non-Chair member of Nominating and Corporate Governance Committee: $5,000 B. E..."
06/09/2023 4 Goeltz II Robert C. (CFO) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Sold 4,049 shares @ $20.04, valued at $81.1k
06/07/2023 144 Form 144 - Report of proposed sale of securities:
05/15/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update • Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. • The third dose-escalation cohort of ARC-20 for AB521, a potential best-in-class HIF-2a inhibitor, is enrolling; the dose-expansion stage of ARC-20 and a Phase 2 combination study in clear-cell renal cell carcinoma patients are expected to begin in the third quarter. • Three new drug candidates are expected to advance into the clinic in 2023 and early 2024. • With $1.0 billion in cash, cash equivalents and marketable securities and funding into 2026, Arcus is well-positioned to advance its pipeline. HAYWARD, Calif. – – May 9, 2023 – ..."
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/20/2023 4 Jarrett Jennifer (COO) has filed a Form 4 on Arcus Biosciences, Inc.
Txns: Sold 8,729 shares @ $16.81, valued at $146.7k
03/10/2023 3 Azoy Alexander (Chief Accounting Officer) has filed a Form 3 on Arcus Biosciences, Inc.
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
02/14/2023 SC 13G/A PFM Health Sciences, LP reports a 3.7% stake in Arcus Biosciences, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy